- Home
- CTSO
as 03-25-2025 4:00pm EST
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 61.3M | IPO Year: | N/A |
| Target Price: | $4.67 | AVG Volume (30 days): | 90.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $1.61 | Next Earning Date: | 05-08-2025 |
| Revenue: | $37,739,531 | Revenue Growth: | 1.80% |
| Revenue Growth (this year): | 9.2% | Revenue Growth (next year): | 11.64% |
Latest Cytosorbents Corporation News
CTSO Breaking Stock News: Dive into CTSO Ticker-Specific Updates for Smart Investing
GuruFocus.com
2 days ago
CytoSorbents Corp (CTSO) Q4 2024 Earnings Report Preview: What to Look For
PR Newswire
5 days ago
CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit
Simply Wall St.
16 days ago
Cytosorbents (NASDAQ:CTSO) shareholders have endured a 78% loss from investing in the stock five years ago
GuruFocus.com
21 days ago
CytoSorbents Corp (CTSO) Q4 2024 Earnings Report Preview: What To Expect
GlobeNewswire
22 days ago
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
GlobeNewswire
a month ago
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire
a month ago
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
TipRanks
2 months ago
Cytosorbents Boosts Liquidity with Successful Rights Offering
Compare CTSO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTSO Cytosorbents Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.